Researcher index

Authors in the psilocybin and psilocin literature

Search researcher names, inspect publication history, find recurring topics, and create author watch alerts without collecting unverified contact lists.

C Barbosa D

85 indexed publications match this author name.

ORCID: Not found in stored metadata
OpenAlex: Not found in stored metadata

Author watchlist

Create a confirmed email alert for new publications matching this author.

Topics

Safety 33 Depression 31 Mechanism of Action 26 Clinical Trial 23 Review Article 22 Receptor Pharmacology 21 Aging 14 Treatment-Resistant Depression 13 Brain Imaging 13 Adverse Events 12 Addiction 11 Observational Study 10

Journals

ClinicalTrials.gov 6 Journal of affective disorders 4 Neuropsychiatric disease and treatment 4 medRxiv 3 Journal of psychopharmacology (Oxford, England) 3 Therapeutic advances in psychopharmacology 3 Nature 3 Npj mental health research 2

Publication history

Reply to 'Methodological concerns and interpretative limitations of assessing subjective effects of ketamine'.Npj mental health research · 2026-09-22 Psilocybin in the Treatment of Methamphetamine Use DisorderClinicalTrials.gov · 2026-09-21 A Phase 1b Study to Evaluate the Safety and Tolerability of MLS101 Treatment for Premenstrual Dysphoric Disorder (PMDD)ClinicalTrials.gov · 2026-09-14 Who Is Reached by Supervised Psilocybin Services? Oregon Services Versus National Psilocybin UsemedRxiv · 2026-09-07 AMCP Market Insights: Optimizing managed care approaches to treatment-resistant depression.Journal of managed care & specialty pharmacy · 2026-09-01 Cardiovascular effects associated with acute recreational drug toxicity presentations to the emergency department: a European drug emergencies network (Euro-DEN plus) study.Clinical toxicology (Philadelphia, Pa.) · 2026-09-01 A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10 Classic psychedelics and personality: An updated systematic review.Journal of psychopharmacology (Oxford, England) · 2026-08-01 Beyond Monoamines: Ketamine, Esketamine, and Classic Psychedelics in the Treatment of DepressionZenodo (CERN European Organization for Nuclear Research) · 2026-07-17 Psilocybin-Assisted Early Palliative Care for Demoralization and Chronic Pain: An Open-Label Pilot Study.medRxiv: the preprint server for health sciences · 2026-07-14 Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: A Randomized Phase II Clinical Trial Comparing One Versus Two Psychedelic Doses of Psilocybin (PSI-1V2)ClinicalTrials.gov · 2026-07-09 Sustained Effects of Low-to-Moderate Doses of Psilocybin on Brain ConnectivitymedRxiv · 2026-04-20 Enhancing cGMP signaling with psilocybin reduces head twitch and restructures the synaptic proteome while maintaining antidepressant responsebioRxiv · 2026-03-10 Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532].Journal of affective disorders · 2026-01-15 Development of Psilocybe Mushroom Species Reference Material-Cultivation Parameters and Chemical Profiles.Journal of AOAC International · 2026-01-01 Toward Standardized Products Containing Biomass of Psilocybe Cubensis Fungi.Journal of AOAC International · 2026-01-01 Pharmacological characterisation of psilocybin and 5-MeO-DMT discriminative cues in the rat and their translational value for identifying novel psychedelics.Journal of psychopharmacology (Oxford, England) · 2026-01-01 Psychedelic therapy and postpartum depression: priorities and prospects.Therapeutic advances in psychopharmacology · 2026-01-01 Phylogenomic systematics of (Boletaceae) reveals cryptic diversity, resolves global evolutionary relationships, and suggests a novel psychoactive lineage.Mycologia · 2026-01-01 A Systematic Review of the efficacy, safety, and Tolerability of Psychedelics in the Treatment of post-traumatic Stress DisorderCurrent Treatment Options in Psychiatry · 2025-12-25 Sex-specific role of the 5-HT receptor in psilocybin-induced extinction of opioid reward.Nature communications · 2025-11-20 Long-term outcomes of single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - 12-month data from an open-label pilot study.Journal of affective disorders · 2025-11-15 Publisher Correction: Psilocybin's lasting action requires pyramidal cell types and 5-HT2A receptors.Nature · 2025-10-01 A critical evaluation of psilocybin-assisted therapy protocol components from clinical trial patients, facilitators, and caregivers.Psychotherapy (Chicago, Ill.) · 2025-09-01 Set and setting of psychedelics for therapeutic use in psychiatry: A systematic review.Journal of psychopharmacology (Oxford, England) · 2025-09-01 Global Increases in Brain Glucose Metabolism Following Acute N,N-Dimethyltryptamine and Harmine Administration in Healthy Volunteers: An [¹⁸F]FDG-PET StudyResearch Square · 2025-07-27 Psilocybin's lasting action requires pyramidal cell types and 5-HT receptors.Nature · 2025-06-01 Understanding the Psychological Effects of Psilocybin and 3,4-Methylenedioxymethamphetamine in a Non-Clinical PopulationmedRxiv · 2025-05-29 Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2025-05-01 Consistent evidence that brain serotonin 2A receptor binding is positively associated with personality-based risk markers of depression.The British journal of psychiatry: the journal of mental science · 2025-03-01 The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.Journal of affective disorders · 2025-03-01 A Modern Overview of the Potential Therapeutic Effects of Psilocybin in the Treatment of Depressive Disorders, Treatment-Resistant Depression, and End-of-Life Distress.Cureus · 2025-03-01 Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper.European psychiatry: the journal of the Association of European Psychiatrists · 2025-01-10 Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity.Neuropsychiatric disease and treatment · 2025-01-01 Novel psychedelic interventions for post-traumatic stress disorder and their promise for precision medicine.Therapeutic advances in psychopharmacology · 2025-01-01 Theoretical Description for Psilocin and Coprine Electrochemical Determination in Mushroom Pulp and Biological Liquids over Cobalt (II) Oxyhydroxide-Modified ElectrodeLetters in Applied NanoBioScience · 2024-12-30 Pyramidal cell types and 5-HT receptors are essential for psilocybin's lasting drug action.bioRxiv: the preprint server for biology · 2024-11-03 Meta-correlation of the effect of ketamine and psilocybin induced subjective effects on therapeutic outcome.Npj mental health research · 2024-10-06 Understanding Psychedelic-Assisted Psychotherapy Providers' Perspective and Insights: A Qualitative Analysis.Psychedelic medicine (New Rochelle, N.Y.) · 2024-09-01 Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocolWellcome Open Res · 2024-07-24 Structural pharmacology and therapeutic potential of 5-methoxytryptamines.Nature · 2024-06-01 Comparing Neural Correlates of Consciousness: From Psychedelics to Hypnosis and Meditation.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2024-05-01 Prefrontal Electrophysiological Biomarkers and Mechanism-Based Drug Effects in a Rat Model of Alcohol AddictionResearch Square · 2024-02-22 Psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alcohol use disorder: an fMRI pilot study.Scientific reports · 2024-02-07 Behavioural Investigations of Psilocybin in Animals 1962-2021: A Scoping ReviewbioRxiv · 2024-01-05 The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.Current neuropharmacology · 2024-01-01 Trauma-Informed Care in Psychedelic Therapy Research: A Qualitative Literature Review of Evidence-Based Psychotherapy Interventions in PTSD and Psychedelic Therapy Across Conditions.Neuropsychiatric disease and treatment · 2024-01-01 Corrigendum: Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings.Frontiers in psychiatry · 2024-01-01 Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: results from an open-label phase Ib ascending dose study.Headache · 2024-01-01 Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol.Wellcome open research · 2024-01-01 An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1).Pilot and feasibility studies · 2023-10-05 Psychedelics promote plasticity by directly binding to BDNF receptor TrkB.Nature neuroscience · 2023-06-01 Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life.Journal of affective disorders · 2023-04-14 Safety and Efficacy of Psilocybin for Body Dysmorphic DisorderClinicalTrials.gov · 2023-03-13 UNRAVELing the synergistic effects of psilocybin and environment on brain-wide immediate early gene expression in mice.bioRxiv: the preprint server for biology · 2023-02-21 Use of Selective Alternative Therapies for Treatment of OCD.Neuropsychiatric disease and treatment · 2023-01-01 Bedside to bench: the outlook for psychedelic research.Frontiers in pharmacology · 2023-01-01 Predicting the Intensity of Psychedelic-Induced Mystical and Challenging Experience in a Healthy Population: An Exploratory Post-Hoc Analysis.Neuropsychiatric disease and treatment · 2023-01-01 Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings.Frontiers in psychiatry · 2023-01-01 Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.The New England journal of medicine · 2022-11-03 Psilocybin Therapy for Treatment Resistant Depression: Prediction of Clinical Outcome by Natural Language ProcessingPsyArXiv · 2022-09-30 Association between Lifetime Classic Psychedelic Use and Sick Leave in a Population-Based Sample.International journal of environmental research and public health · 2022-09-09 Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges.Expert opinion on drug safety · 2022-06-01 Diversity, biology, and history of psilocybin-containing fungi: Suggestions for research and technological development.Fungal biology · 2022-04-01 Effects of Ayahuasca on the Recognition of Facial Expressions of Emotions in Naive Healthy Volunteers: A Pilot, Proof-of-Concept, Randomized Controlled Trial.Journal of clinical psychopharmacology · 2021-01-01 MDMA-induced changes in within-network connectivity contradict the specificity of these alterations for the effects of serotonergic hallucinogensNeuropsychopharmacology · 2020-11-19 Long-term effects of psychedelic drugs: A systematic review.Neuroscience and biobehavioral reviews · 2020-06-01 Scoping Review Protocol: Mapping Psilocybin Animal ResearchQueen's University QSpace · 2020-05-20 Scoping Review Protocol: Mapping Psilocybin Therapy ResearchQueen's University QSpace · 2020-05-20 [Addictions].Revue medicale suisse · 2020-01-15 Reported effects of psychedelic use on those with low well-being given various emotional states and social contextsDrug Science Policy and Law · 2020-01-01 Psychedelic microdosing benefits and challenges: an empirical codebook.Harm reduction journal · 2019-07-10 2018: A watershed year for psychedelic scienceDrug Science Policy and Law · 2019-01-01 Serotonergic hallucinogens and recognition of facial emotion expressions: a systematic review of the literature.Therapeutic advances in psychopharmacology · 2019-01-01 Microdosing Psychedelics: Personality, mental health, and creativity differences in microdosersPsyArXiv · 2018-11-02 Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term MeditatorsClinicalTrials.gov · 2014-05-20 Potential Therapeutic Effects of Psilocybin/Psilocin are Minimized While Possible Adverse Reactions are OverratedTherapeutic Drug Monitoring · 2014-02-01 Fungal Hallucinogens Psilocin, Ibotenic Acid, and MuscimolTherapeutic Drug Monitoring · 2013-08-01 Drugs of abuse monitoring in blood for control of driving under the influence of drugs.Therapeutic drug monitoring · 2002-04-01 Profiles of psychedelic drugs. Psilocybin.Journal of psychedelic drugs · 1980-01-01 Psilocin, Bufotenine and Serotonin: Historical and Biosynthetic ObservationsJournal of Psychedelic Drugs · 1979-01-01 The Psilocybin Mushroom PandemicJournal of Psychedelic Drugs · 1975-01-01 Psilocybin reactivity and time contraction as measured by psychomotor performance.Arzneimittel-Forschung · 1966-02-01 [COMPARISON OF PSYCHOPHARMACA LSD-25, BOL-148 AND PSILOCYBIN IN CLINICAL PRACTICE].Vojnosanitetski pregled · 1963-05-01 [OUR CLINICAL EXPERIENCE WITH A NEW PHARMACOLOGICAL PREPARATION PSILOCYBIN].Neuropsihijatrija · 1963-01-01

Author directory